
|Videos|January 30, 2023
The Role of Ruxolitinib in Myelofibrosis Treatment
Author(s)Joshua Richter, MD, Srdan Verstovsek, MD, PhD
Dr Srdan Verstovsek discusses how ruxolitinib might fit into the myelofibrosis treatment landscape in the future, and highlights remaining unmet needs.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















